SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics announced that an abstract featuring its…

MiNK Therapeutics · PRESS-RELEASE filed Apr 1, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Apr 1, 2026 at 07:30 ET

MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination with N-803 for severe Coccidioides infection, has been accepted for presentation at the ATS International Conference in May 2026. No data will be disclosed ahead of the conference, and full results will be shared during the poster session. This represents early-stage clinical visibility but no new efficacy or safety results.

  • Abstract on agenT-797 combination therapy accepted for poster presentation at ATS 2026 conference.
  • Presentation will occur on May 20, 2026, in Orlando, Florida; no data released in advance.
  • agenT-797 is in clinical development for GvHD, solid tumors, and severe pulmonary inflammation.
  • No financial or clinical results disclosed; next update expected at the conference.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access